Clinical Scorecard: Live Roundtable: What Is the Biggest Bottleneck Holding Back Cell and Gene Therapy?
At a Glance
Category
Detail
Condition
Cell and gene therapy development and access
Key Mechanisms
The article describes operational and system-level barriers, including complex manufacturing, fragmented data systems, regulatory requirements, limited care sites, and uncertain reimbursement.
Target Population
Cell and gene therapy ecosystem stakeholders; no patient population is specified.
Care Setting
Cell and gene therapy development, manufacturing, regulation, and delivery settings.
Key Highlights
The roundtable examines barriers to making cell and gene therapies widely accessible.
Topics include manufacturing complexity, fragmented data systems, regulatory requirements, limited care sites, and uncertain reimbursement.
Participants consider which bottlenecks warrant greater industry focus and where collaboration is needed.
The discussion considers AI and other emerging technologies as possible tools for addressing barriers.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
The article identifies complex manufacturing, fragmented data systems, demanding regulatory requirements, limited sites of care, and uncertain reimbursement as potential barriers to progress.
Patient & Prescribing Data
No specific patient population or prescribing information is provided.
The article discusses cell and gene therapy access and development challenges; it provides no treatment protocols or prescribing guidance.
Hematologist and medical oncologist Ashley Marton, M.D.C.M., has joined the Eugene M. and Christine E. Lynn Cancer Institute - Boynton Beach, part of Baptist Health Cancer Care
